- Published on
KembaraXtra-Medicine – Anxiety (Generalized Anxiety Disorder)
Generalized anxiety disorder (GAD) is a chronic psychiatric condition that commonly presents alongside other psychiatric or medical illnesses. According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), GAD is characterized by excessive, persistent, and disproportionate anxiety or worry occurring on most days for at least six months. This worry involves multiple life domains such as work, health, finances, or family and causes significant impairment in daily functioning. The anxiety is accompanied by physical or cognitive symptoms, including restlessness, irritability, muscle tension, sleep disturbance, fatigue, and difficulty concentrating. The diagnosis cannot be made if the symptoms are better explained by another anxiety disorder, mood disorder, substance use, or medical condition.
GAD is relatively common, with a lifetime prevalence of approximately 5% in the general U.S. population and a point prevalence of 2% to 3%. It is the most frequently encountered anxiety disorder in primary care settings. Women are affected about twice as often as men, although men may be less likely to seek treatment. Onset can occur at any age, with nearly half of patients reporting symptoms beginning before age 18, and a median age of onset around 30 years. Genetic contributions appear modest, as twin studies show low concordance rates.
Clinically, patients often describe themselves as having been anxious for most of their lives. Excessive worry is typically accompanied by sleep disturbance, particularly difficulty falling asleep, chronic muscle tension (often in the neck and shoulders), headaches, fatigue, and impaired concentration. Many patients present with somatic complaints such as gastrointestinal symptoms, palpitations, or chest tightness rather than overt psychological distress. Comorbid conditions are common and include major depressive disorder, dysthymia, substance use disorders, and chronic pain syndromes.
The etiology of GAD is multifactorial and includes neurobiologic, psychological, and environmental components. Proposed mechanisms involve dysregulation of neurotransmitters such as serotonin, norepinephrine, and gamma-aminobutyric acid (GABA), as well as personality traits like behavioral inhibition and neuroticism. Risk is increased by family history, chronic stress, trauma exposure, and medical illness. Modifiable risk factors include tobacco use, alcohol or cannabis use, and occupational stress.
Diagnosis requires careful evaluation to exclude other psychiatric disorders and medical causes of anxiety, such as thyroid disease, cardiac arrhythmias, substance intoxication or withdrawal, and other anxiety disorders. Screening tools such as the GAD-2 and GAD-7 questionnaires are commonly used in primary care to aid detection and assess symptom severity. Additional laboratory or imaging studies are guided by the patient’s presentation and clinical suspicion for secondary causes.
Management of GAD typically involves a combination of psychotherapeutic and pharmacologic approaches. Cognitive-behavioral therapy is a first-line nonpharmacologic treatment and has strong evidence for efficacy. Other effective approaches include acceptance and commitment therapy, mindfulness-based interventions, relaxation training, and psychodynamic psychotherapy. Pharmacologic treatment most commonly includes selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors, which have response rates of approximately 60% to 75%. Buspirone and pregabalin are additional effective options, while benzodiazepines are generally reserved for short-term or refractory cases due to risks of dependence and cognitive impairment.
GAD is a chronic condition with fluctuating severity over time. Treatment focuses on reducing symptom burden, improving functioning, and preventing complications such as major depression or suicidality. Referral to mental health specialists is appropriate for patients with refractory symptoms, diagnostic uncertainty, or significant psychiatric comorbidity. Early recognition and sustained treatment can substantially improve long-term outcomes and quality of life.
Generalized anxiety disorder (GAD) is a chronic psychiatric condition that commonly presents alongside other psychiatric or medical illnesses. According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), GAD is characterized by excessive, persistent, and disproportionate anxiety or worry occurring on most days for at least six months. This worry involves multiple life domains such as work, health, finances, or family and causes significant impairment in daily functioning. The anxiety is accompanied by physical or cognitive symptoms, including restlessness, irritability, muscle tension, sleep disturbance, fatigue, and difficulty concentrating. The diagnosis cannot be made if the symptoms are better explained by another anxiety disorder, mood disorder, substance use, or medical condition.
GAD is relatively common, with a lifetime prevalence of approximately 5% in the general U.S. population and a point prevalence of 2% to 3%. It is the most frequently encountered anxiety disorder in primary care settings. Women are affected about twice as often as men, although men may be less likely to seek treatment. Onset can occur at any age, with nearly half of patients reporting symptoms beginning before age 18, and a median age of onset around 30 years. Genetic contributions appear modest, as twin studies show low concordance rates.
Clinically, patients often describe themselves as having been anxious for most of their lives. Excessive worry is typically accompanied by sleep disturbance, particularly difficulty falling asleep, chronic muscle tension (often in the neck and shoulders), headaches, fatigue, and impaired concentration. Many patients present with somatic complaints such as gastrointestinal symptoms, palpitations, or chest tightness rather than overt psychological distress. Comorbid conditions are common and include major depressive disorder, dysthymia, substance use disorders, and chronic pain syndromes.
The etiology of GAD is multifactorial and includes neurobiologic, psychological, and environmental components. Proposed mechanisms involve dysregulation of neurotransmitters such as serotonin, norepinephrine, and gamma-aminobutyric acid (GABA), as well as personality traits like behavioral inhibition and neuroticism. Risk is increased by family history, chronic stress, trauma exposure, and medical illness. Modifiable risk factors include tobacco use, alcohol or cannabis use, and occupational stress.
Diagnosis requires careful evaluation to exclude other psychiatric disorders and medical causes of anxiety, such as thyroid disease, cardiac arrhythmias, substance intoxication or withdrawal, and other anxiety disorders. Screening tools such as the GAD-2 and GAD-7 questionnaires are commonly used in primary care to aid detection and assess symptom severity. Additional laboratory or imaging studies are guided by the patient’s presentation and clinical suspicion for secondary causes.
Management of GAD typically involves a combination of psychotherapeutic and pharmacologic approaches. Cognitive-behavioral therapy is a first-line nonpharmacologic treatment and has strong evidence for efficacy. Other effective approaches include acceptance and commitment therapy, mindfulness-based interventions, relaxation training, and psychodynamic psychotherapy. Pharmacologic treatment most commonly includes selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors, which have response rates of approximately 60% to 75%. Buspirone and pregabalin are additional effective options, while benzodiazepines are generally reserved for short-term or refractory cases due to risks of dependence and cognitive impairment.
GAD is a chronic condition with fluctuating severity over time. Treatment focuses on reducing symptom burden, improving functioning, and preventing complications such as major depression or suicidality. Referral to mental health specialists is appropriate for patients with refractory symptoms, diagnostic uncertainty, or significant psychiatric comorbidity. Early recognition and sustained treatment can substantially improve long-term outcomes and quality of life.
0 Comments
